Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study
Limited benefit with significant toxicity for pembro + olaparib for patients after docetaxel with mCRPC.